Allergan: This $64,000 Question Could Kill Restasis IPR Appeal

Allergan (AGN) is known as one of the more litigious drug companies out there. It has carved out a reputation for being highly-acquisitive and for doggedly protecting its drug patents. The company may have broken the mold after it sold its Restasis patents to the St. Regis Mohawks; in my opinion, Allergan was attempting to “rent” the Mohawks’ sovereign immunity in order to protect Restasis patents from an inter partes review (“IPR”) from Mylan (MYL).